Literature DB >> 16259988

Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound.

Marta Miguel Turu1, Jerzy Krupinski, Esther Catena, Ana Rosell, Joan Montaner, Francisco Rubio, Jose Alvarez-Sabin, Marc Cairols, Lina Badimon.   

Abstract

Carotid atherosclerotic plaque remodelling and increased risk of symptomatic plaque rupture seem to be partially mediated by matrix metalloproteinases (MMPs). In this study, we have investigated whether different MMPs are related to carotid atherosclerosis or to recent ischaemic brain disease. Eighty-four consecutive patients undergoing carotid endarterectomy for symptomatic and asymptomatic disease were studied. Plaques were analysed by ultrasound and later by morphology. Plasma MMP-2, MMP-8 and MMP-9 levels were quantified by ELISA. MMP expression and activity in carotid plaques was analysed by Western blotting and in situ zymography. Results were analysed with respect to plaque stability, morphology, symptomatic disease, presence of vascular risk factors and plasma markers of acute inflammation as high sensitivity C-reactive protein (hsCRP), fibrinogen, D-dimer and white blood cell counts. Patients with hypoechogenic plaques on ultrasound had more plasma MMP-8 (p = 0.04) and increased MMP activity as assessed by in situ zymography. Asymptomatic patients with plaque progression had more active intraplaque MMP-8 than asymptomatic patients without plaque progression. Presence of recent intraplaque haemorrhage or past history of CAD was related to increased activity of MMPs as assessed by in situ zymography (p < 0.01, CI 95% 0.8-1.0). Plasma MMP-8 and MMP-9, but not MMP-2 levels, decrease with time after ischaemic stroke. Patients with hypertension had more intraplaque active MMP-9 than normotensive (p = 0.03, CI 95% 0.7-1.0). Hypoechogenic carotid plaques had increased MMP activity and asymptomatic patients with plaque progression show increase intraplaque MMP-8 levels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16259988     DOI: 10.1016/j.atherosclerosis.2005.08.039

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  26 in total

Review 1.  The role of matrix metalloproteinases in atherothrombosis.

Authors:  Daniel F J Ketelhuth; Magnus Bäck
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

2.  Plasma levels of matrix metalloproteinase-8 in patients with carotid atherosclerosis.

Authors:  Tamara Djurić; Maja Zivković; Aleksandra Stanković; Ana Kolaković; Djole Jekić; Vesna Selaković; Dragan Alavantić
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

3.  Macrophage-derived MMP-8 determines smooth muscle cell differentiation from adventitia stem/progenitor cells and promotes neointima hyperplasia.

Authors:  Feng Yang; Qishan Chen; Mei Yang; Eithne Margaret Maguire; Xiaotian Yu; Shiping He; Rui Xiao; Claire S Wang; Weiwei An; Wei Wu; Yijiang Zhou; Qingzhong Xiao; Li Zhang
Journal:  Cardiovasc Res       Date:  2020-01-01       Impact factor: 10.787

4.  Tissue Factor, Tissue Factor Pathway Inhibitor and Factor VII Activity in Cardiovascular Complicated Type 2 Diabetes Mellitus.

Authors:  Rehab S El-Hagracy; Gihan M Kamal; Inas M Sabry; Abeer A Saad; Nahla F Abou El Ezz; Hesham A R Nasr
Journal:  Oman Med J       Date:  2010-07

Review 5.  An emerging role of degrading proteinases in hypertension and the metabolic syndrome: autodigestion and receptor cleavage.

Authors:  Geert W Schmid-Schönbein
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

6.  Matrix metalloproteinases in cerebral ischemia.

Authors:  Hahn Young Kim; Seol-Heui Han
Journal:  J Clin Neurol       Date:  2006-09-20       Impact factor: 3.077

7.  Changes in Hyaluronan Metabolism and RHAMM Receptor Expression Accompany Formation of Complicated Carotid Lesions and May be Pro-Angiogenic Mediators of Intimal Neovessel Growth.

Authors:  Jerzy Krupinski; Priya Ethirajan; M Angels Font; Marta Miguel Turu; John Gaffney; Pat Kumar; Mark Slevin
Journal:  Biomark Insights       Date:  2008-05-12

8.  MicroRNA-539 suppresses osteosarcoma cell invasion and migration in vitro and targeting Matrix metallopeptidase-8.

Authors:  Hui Jin; Wenbo Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

9.  The effect of prolonged systemic doxycycline therapy on serum tissue degrading proteinases in coronary bypass patients: a randomized, double-masked, placebo-controlled clinical trial.

Authors:  Immi Kormi; Hatem Alfakry; Taina Tervahartiala; Pirkko J Pussinen; Juha Sinisalo; Timo Sorsa
Journal:  Inflamm Res       Date:  2013-12-31       Impact factor: 4.575

10.  A role of matrix metalloproteinase-8 in atherosclerosis.

Authors:  Ross C Laxton; Yanhua Hu; Johan Duchene; Feng Zhang; Zhongyi Zhang; Kit-Yi Leung; Qingzhong Xiao; Ramona S Scotland; Conrad P Hodgkinson; Katherine Smith; Johann Willeit; Carlos López-Otín; Iain A Simpson; Stefan Kiechl; Amrita Ahluwalia; Qingbo Xu; Shu Ye
Journal:  Circ Res       Date:  2009-09-10       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.